JPMorgan Chase & Co. Acquires 26,893 Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

JPMorgan Chase & Co. grew its stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) by 250.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,619 shares of the company’s stock after acquiring an additional 26,893 shares during the period. JPMorgan Chase & Co. owned 0.15% of Artiva Biotherapeutics worth $379,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter valued at $52,000. Barclays PLC purchased a new stake in Artiva Biotherapeutics in the third quarter valued at $304,000. Charles Schwab Investment Management Inc. grew its stake in shares of Artiva Biotherapeutics by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares during the period. State Street Corp acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $1,337,000. Finally, Geode Capital Management LLC acquired a new position in Artiva Biotherapeutics during the third quarter worth $4,774,000.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, April 8th. Cantor Fitzgerald decreased their price target on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, March 26th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $2.37 on Friday. The business’s fifty day moving average price is $3.41 and its 200 day moving average price is $7.28. Artiva Biotherapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $17.31.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.